ClinicalTrials.gov record
Terminated Phase 2 Interventional

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

ClinicalTrials.gov ID: NCT00606476

Public ClinicalTrials.gov record NCT00606476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102

Study identification

NCT ID
NCT00606476
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Enrollment
194 participants

Conditions and interventions

Interventions

  • Bapineuzumab (AAB-001) Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012
Last update posted
Nov 24, 2013

2006 – 2012

United States locations

U.S. sites
29
U.S. states
20
U.S. cities
29
Facility City State ZIP Site status
Janssen AI Investigational Site Peoria Arizona 85381
Janssen AI Investigational Site Sun City Arizona 85351
Janssen AI Investigational Site Encino California 91316
Janssen AI Investigational Site Irvine California 92697
Janssen AI Investigational Site La Jolla California 92037
Janssen AI Investigational Site Los Alamitos California 90720
Janssen AI Investigational Site Sacramento California 95817
Janssen AI Investigational Site San Francisco California 94143
Janssen AI Investigational Site New Haven Connecticut 06510
Janssen AI Investigational Site Washington D.C. District of Columbia 20057
Janssen AI Investigational Site Delray Beach Florida 33445
Janssen AI Investigational Site Jacksonville Florida 32224
Janssen AI Investigational Site Chicago Illinois 60612
Janssen AI Investigational Site Indianapolis Indiana 46202
Janssen AI Investigational Site Boston Massachusetts 02115
Janssen AI Investigational Site Ann Arbor Michigan 48105
Janssen AI Investigational Site Rochester Minnesota 55905
Janssen AI Investigational Site St Louis Missouri 63108
Janssen AI Investigational Site Eatontown New Jersey 07724
Janssen AI Investigational Site New York New York 10032
Janssen AI Investigational Site Rochester New York 14620
Janssen AI Investigational Site Durham North Carolina 27710
Janssen AI Investigational Site Portland Oregon 97239
Janssen AI Investigational Site Pittsburgh Pennsylvania 15213
Janssen AI Investigational Site Providence Rhode Island 02906
Janssen AI Investigational Site Dallas Texas 75390
Janssen AI Investigational Site Houstan Texas 77030
Janssen AI Investigational Site Bennington Vermont 05201
Janssen AI Investigational Site Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00606476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2013 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00606476 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →